Atlas Trials

Study of Zanubrutinib (BGB-3111) in Participants With Marginal Zone Lymphoma

Clinical trial NCT03846427 · COMPLETED

Trial details

NCT number
NCT03846427
Sponsor
BeiGene
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Marginal Zone LymphomaMZL
Start date
2019-02-19
Primary completion
2022-05-04
Enrollment
68

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.